-Treatment with Lyo avexitide reduced the magnitude of symptomatic hyperinsulinemic hypoglycemia at all dose levels, with dose-dependent improvements in glucose nadir, insulin peak, and symptom score.-Liqavexitide 30 mg BID significantly increased glucose nadir (+47%), reduced insulin peak (−67%), and reduced overall symptom score (−47%).-Both formulations were well tolerated. Here, INS is linked to hyperinsulinemic hypoglycemia.